Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.31 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24429364 | 0.81 | SLC6A2 (0.36) | SLC6A2SLC6A4PIK3CDCHI3L1KCNH2 | |
| SCHEMBL18248893 | 0.79 | SLC6A2 (0.38) | SLC6A2SLC6A4PIK3CDCHI3L1KCNH2 | |
| SCHEMBL22200611 | 0.79 | SLC6A2 (0.35) | SLC6A2SLC6A4PIK3CDCHI3L1KCNH2 | |
| SCHEMBL22200610 | 0.78 | SLC6A2 (0.37) | SLC6A2SLC6A4PIK3CDCHI3L1KCNH2 | |
| SCHEMBL24429539 | 0.78 | SLC6A2 (0.35) | SLC6A2SLC6A4PIK3CDCHI3L1KCNH2 | |
| SCHEMBL24429521 | 0.76 | SLC6A2 (0.37) | SLC6A2SLC6A4PIK3CDCHI3L1KCNH2 | |
| SCHEMBL21386060 | 0.76 | SLC6A2 (0.34) | SLC6A2SLC6A4PIK3CDCHI3L1KCNH2 | |
| SCHEMBL21038725 | 0.75 | SLC6A2 (0.55) | SLC6A2SLC6A4PIK3CDKCNH2CHIT1 | |
| SCHEMBL5857573 | 0.75 | SLC6A2 (0.35) | SLC6A2SLC6A4PIK3CDCHI3L1KCNH2 | |
| SCHEMBL14160972 | 0.75 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | SLC6A2 4865/4885SLC6A4 4860/4885PIK3CD 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.